Add a Mineralocorticoid Receptor Antagonist (Spironolactone)
For this patient with resistant hypertension already on irbesartan 300 mg and amlodipine 5 mg, add spironolactone (a mineralocorticoid receptor antagonist) as the next agent—this is a non-sulfonamide medication that is specifically recommended by current guidelines for resistant hypertension. 1, 2
Why Spironolactone is the Optimal Choice
The patient's current regimen (ARB + CCB) represents two components of optimal first-line therapy. According to the 2025 AHA/ACC guidelines, resistant hypertension is defined as uncontrolled BP despite optimal treatment with an ACE inhibitor or ARB plus CCB and a thiazide-like diuretic 1. Since this patient cannot take thiazide-like diuretics (chlorthalidone and indapamide are sulfonamide derivatives), the next step is to proceed directly to fourth-line therapy.
Both the 2025 AHA/ACC and 2024 ESC guidelines explicitly recommend adding a mineralocorticoid receptor antagonist (MRA) as the preferred fourth-line agent for resistant hypertension 1, 2. The 2025 AHA/ACC guideline states that in adults with uncontrolled resistant hypertension and eGFR ≥45 mL/min/1.73 m², "addition of a MRA is recommended to control BP" 1.
The 2024 ESC guideline similarly recommends "addition of low-dose spironolactone to existing treatment" as first-line therapy for resistant hypertension 2.
Alternative Non-Sulfonamide Options
If spironolactone is contraindicated or not tolerated, the guidelines provide a clear hierarchy of alternatives—all of which are non-sulfonamide medications 1, 2:
- Amiloride (potassium-sparing diuretic, not a sulfonamide)
- Eplerenone (selective MRA)
- Beta-blockers (e.g., bisoprolol)
- Alpha-blockers (e.g., doxazosin)
- Central sympatholytic drugs (e.g., clonidine)
- Direct vasodilators (e.g., hydralazine)
Important Caveats About Sulfonamide Allergy
Critical distinction: Loop diuretics (furosemide, bumetanide, torsemide) and thiazide/thiazide-like diuretics (hydrochlorothiazide, chlorthalidone, indapamide) are sulfonamide derivatives and should be avoided in patients with sulfa allergy. However, spironolactone, eplerenone, and amiloride are NOT sulfonamides and can be safely used.
Before Adding Medication
The 2025 AHA/ACC guideline emphasizes that before escalating therapy, perform a "more detailed evaluation for secondary causes" and "careful review of all medications and removal of those with interfering effects on BP" 1. Approximately 20% of hypertensive adults use over-the-counter medications (NSAIDs, nasal decongestants) that can raise BP or interfere with antihypertensive efficacy 1.
The 2024 ESC guideline adds that "reinforcement of lifestyle measures, especially sodium restriction" should accompany medication intensification 2.
Monitoring Requirements
When initiating spironolactone, monitor:
- Serum potassium (risk of hyperkalemia, especially with concurrent ARB use)
- Renal function (ensure eGFR ≥45 mL/min/1.73 m² per AHA/ACC, though ESC is less restrictive)
- Start with low-dose spironolactone (typically 12.5-25 mg daily) and titrate as needed
Why Not Increase Current Medications?
While research shows that increasing amlodipine from 5 mg to 10 mg can provide additional BP reduction 3, and the patient is already on maximum-dose irbesartan 4, guidelines prioritize adding a fourth agent from a different class (MRA) over maximizing doses of existing medications in resistant hypertension 1, 2. This multi-mechanistic approach targets different pathophysiologic pathways.